Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) issued an update on its FY16 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $5.10-5.20 for the period, compared to the Thomson Reuters consensus estimate of $5.18. The company issued revenue guidance of $21.6-21.9, compared to the consensus revenue estimate of $22.10 billion.Teva Pharmaceutical Industries also updated its Q4 guidance to $1.34-1.44 EPS.

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) opened at 38.07 on Thursday. Teva Pharmaceutical Industries Ltd. has a 52-week low of $37.25 and a 52-week high of $66.55. The stock’s 50 day moving average price is $42.97 and its 200-day moving average price is $49.87. The firm has a market capitalization of $34.80 billion, a PE ratio of 25.43 and a beta of 0.73.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Tuesday, November 15th. The company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.29 by $0.02. The firm earned $5.56 billion during the quarter, compared to the consensus estimate of $5.71 billion. Teva Pharmaceutical Industries had a net margin of 7.56% and a return on equity of 17.77%. The company’s revenue was up 15.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.35 earnings per share. Equities research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post $5.16 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 20th. Investors of record on Monday, December 5th will be paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.57%. Teva Pharmaceutical Industries’s payout ratio is currently 58.39%.

TEVA has been the subject of a number of research reports. OTR Global initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Thursday, September 29th. They issued a positive rating for the company. Maxim Group set a $72.00 target price on shares of Teva Pharmaceutical Industries and gave the company a buy rating in a report on Friday, October 14th. Guggenheim reaffirmed a buy rating and issued a $80.00 target price on shares of Teva Pharmaceutical Industries in a report on Monday, August 15th. JPMorgan Chase & Co. reaffirmed an overweight rating and issued a $75.00 target price on shares of Teva Pharmaceutical Industries in a report on Tuesday, July 26th. Finally, Wells Fargo & Co. reaffirmed a buy rating on shares of Teva Pharmaceutical Industries in a report on Monday, October 3rd. Thirteen analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $60.00.

Several institutional investors have recently modified their holdings of TEVA. WFG Advisors LP increased its position in shares of Teva Pharmaceutical Industries by 14.0% in the second quarter. WFG Advisors LP now owns 2,080 shares of the company’s stock worth $104,000 after buying an additional 256 shares in the last quarter. Citizens Financial Group Inc RI increased its position in shares of Teva Pharmaceutical Industries by 17.1% in the second quarter. Citizens Financial Group Inc RI now owns 2,398 shares of the company’s stock worth $121,000 after buying an additional 351 shares in the last quarter. Krilogy Financial LLC increased its position in shares of Teva Pharmaceutical Industries by 1.0% in the second quarter. Krilogy Financial LLC now owns 2,635 shares of the company’s stock worth $132,000 after buying an additional 25 shares in the last quarter. SevenBridge Financial Group LLC acquired a new position in shares of Teva Pharmaceutical Industries during the second quarter worth approximately $159,000. Finally, WESPAC Advisors SoCal LLC increased its position in shares of Teva Pharmaceutical Industries by 1.4% in the second quarter. WESPAC Advisors SoCal LLC now owns 3,550 shares of the company’s stock worth $178,000 after buying an additional 50 shares in the last quarter. 63.00% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Stock Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.